- Home
- IMXI vs EDIT Comparison
IMXI vs EDIT Comparison
Compare IMXI & EDIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMXI
- EDIT
- Stock Information
- Founded
- IMXI 1994
- EDIT 2013
- Country
- IMXI United States
- EDIT United States
- Employees
- IMXI N/A
- EDIT N/A
- Industry
- IMXI Retail: Computer Software & Peripheral Equipment
- EDIT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- IMXI Technology
- EDIT Health Care
- Exchange
- IMXI Nasdaq
- EDIT Nasdaq
- Market Cap
- IMXI 302.5M
- EDIT 263.7M
- IPO Year
- IMXI N/A
- EDIT 2016
- Fundamental
- Price
- IMXI $9.38
- EDIT $2.28
- Analyst Decision
- IMXI Buy
- EDIT Buy
- Analyst Count
- IMXI 7
- EDIT 12
- Target Price
- IMXI $19.60
- EDIT $6.20
- AVG Volume (30 Days)
- IMXI 328.5K
- EDIT 2.2M
- Earning Date
- IMXI 08-15-2025
- EDIT 08-19-2025
- Dividend Yield
- IMXI N/A
- EDIT N/A
- EPS Growth
- IMXI 1.60
- EDIT N/A
- EPS
- IMXI 1.70
- EDIT N/A
- Revenue
- IMXI $652,547,000.00
- EDIT $35,837,000.00
- Revenue This Year
- IMXI N/A
- EDIT N/A
- Revenue Next Year
- IMXI $2.93
- EDIT N/A
- P/E Ratio
- IMXI $5.42
- EDIT N/A
- Revenue Growth
- IMXI N/A
- EDIT N/A
- 52 Week Low
- IMXI $8.58
- EDIT $0.91
- 52 Week High
- IMXI $22.37
- EDIT $4.90
- Technical
- Relative Strength Index (RSI)
- IMXI 42.96
- EDIT 43.28
- Support Level
- IMXI $8.58
- EDIT $2.37
- Resistance Level
- IMXI $9.57
- EDIT $2.67
- Average True Range (ATR)
- IMXI 0.34
- EDIT 0.23
- MACD
- IMXI 0.03
- EDIT -0.08
- Stochastic Oscillator
- IMXI 47.18
- EDIT 5.37
About IMXI International Money Express Inc.
International Money Express Inc is a processor of money transfer services in the USA to the Latin America and the Caribbean (LAC) corridor. The company offers wire transfer, money order, Foreign exchange, and cash checking services, while the majority of the revenue is derived from wire transfer and money order fees. The firm's business is organized around one reportable segment that provides money remittance services between the U.S. and Canada to Mexico, Guatemala, and other countries in Latin America, Africa, and Asia.
About EDIT Editas Medicine Inc.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.